Breaking News, Collaborations & Alliances

Samsung Biologics, AimedBio Enter ADC Research Pact

To support the development of AimedBio’s monoclonal antibody therapy for atopic dermatitis and dementia.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics joined an equity investment in AimedBio, a Korean biotech company developing antibody-drug conjugate (ADC) technology. The investment was made through the Samsung Life Science Fund. Based on multi-omics and AI-driven big data analysis of patient samples, AimedBio specializes in the discovery and development of medicines for severe neurological diseases, such as brain cancer, Alzheimer’s disease, and Parkinson’s disease. AimedBio has developed a therapeutic pipeline, includin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters